Buying after a heavy sell off due to disappointing trial results
Oversold (as per the chat the stock reacts strongly to being oversold) PPMO data expected in 2Q21 could prove a huge catalyst for shares to go higher
Also - the company is posting strong sales growth (+40% this year) and peak sales estimates are over double current sales of some treatments suggesting sales growth will continue.